Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACARBOSE vs MIGLITOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.
Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in individuals with impaired glucose tolerance
Type 2 diabetes mellitus as monotherapy or in combination with sulfonylureas, metformin, or insulin when diet and exercise do not provide adequate glycemic control
Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.
25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.
Terminal elimination half-life is approximately 2.5 to 3 hours for the parent compound, but the drug acts locally in the GI tract; systemic half-life is not clinically relevant for its pharmacodynamic effect.
Plasma elimination half-life ≈ 2 hours; clinical effect (alpha-glucosidase inhibition) persists longer due to enzyme binding; half-life increases in renal impairment (creatinine clearance < 25 m L/min).
Acarbose is metabolized exclusively within the gastrointestinal tract, primarily by intestinal bacteria and digestive enzymes. Approximately 35% of the dose is absorbed as metabolites, which are excreted via the kidneys. The parent drug is not significantly metabolized by hepatic enzymes.
Not metabolized; excreted unchanged in feces (via enzymatic breakdown in gut lumen) and urine (minor).
Primarily excreted unchanged in feces (approximately 50% of an oral dose) and as metabolites via the gastrointestinal tract; less than 2% of the dose is recovered in urine as active drug or metabolites. Renal excretion is minimal.
Primarily excreted unchanged in urine (≈ 65%) via glomerular filtration; remainder recovered as metabolites in urine (25%) and feces (5%); total recovery in urine and feces ≈ 95% within 24 hours.
Negligible to low protein binding; less than 1-2% bound to plasma proteins, primarily albumin.
Negligible (< 4%), primarily bound to albumin.
Volume of distribution is not well defined due to minimal systemic absorption; estimated to be less than 0.3 L/kg, reflecting limited distribution beyond the gastrointestinal lumen.
Approximately 0.18 L/kg; distributes mainly in extracellular fluid with limited tissue penetration.
Oral: Systemic bioavailability is very low (approximately 0.5-2%) due to local action in the GI tract and minimal absorption. The drug acts locally in the intestine; systemic levels are negligible.
Low and variable oral bioavailability: approximately 50% (range 35–65%) due to incomplete absorption and intestinal metabolism; dose proportional for doses up to 100 mg.
No specific dose adjustment required for GFR ≥25 m L/min; contraindicated in GFR <25 m L/min (creatinine clearance <25 m L/min).
GFR <25 m L/min/1.73m2: contraindicated. No adjustment needed for GFR ≥25 m L/min/1.73m2.
No specific dose adjustment for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (Child-Pugh class C).
No dose adjustment required for hepatic impairment; not studied in Child-Pugh C. Use with caution in severe hepatic disease.
Not recommended for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established in pediatric patients.
Initiate at the lowest dose (25 mg 3 times daily); titrate slowly based on tolerance and glycemic control, as elderly patients may have reduced renal function and higher risk of gastrointestinal adverse effects.
No specific dose adjustment, but monitor renal function; elderly may have age-related decline in renal function. Use lowest effective dose.
None
None.
Risk of hepatotoxicity: rare cases of severe hepatocellular injury, including fulminant hepatitis, reported, especially at higher doses (≥300 mg/day); monitor liver enzymes periodically.,Use with caution in patients with renal impairment (e GFR <25 m L/min/1.73 m²): insufficient data; avoid use.,May cause hypoglycemia when used in combination with sulfonylureas or insulin; treat hypoglycemia with oral glucose (dextrose) rather than sucrose (acarbose inhibits sucrose digestion).,Gastrointestinal adverse effects (flatulence, diarrhea, abdominal pain) are common due to undigested carbohydrate fermentation in the colon; may subside with continued use.,Acute porphyria: acarbose has been associated with acute attacks in susceptible patients.
Hypoglycemia risk when used with insulin or sulfonylureas,Hepatotoxicity (rare, monitor liver enzymes),Gastrointestinal side effects (flatulence, diarrhea, abdominal pain) due to undigested carbohydrates in colon
Hypersensitivity to acarbose or any component of the formulation,Diabetic ketoacidosis,Cirrhosis or significant hepatic impairment,Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Renal impairment (e GFR <25 m L/min/1.73 m²)
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Intestinal obstruction or predisposition to obstruction,Chronic intestinal diseases associated with malabsorption,Hypersensitivity to miglitol
Acarbose delays digestion of complex carbohydrates and sucrose. To reduce gastrointestinal side effects, avoid high-sucrose foods and drinks. Simple sugars like glucose and fructose can still be absorbed and used to treat hypoglycemia. Alcohol may increase the risk of hypoglycemia when combined with acarbose, especially if taken with other antidiabetic agents.
Carbohydrates in the meal may cause increased flatulence and diarrhea. Sucrose and table sugar are not effective for treating hypoglycemia; use pure glucose. Avoid excessive simple carbohydrates if tolerated.
Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposure. Risk cannot be excluded in first trimester. Second and third trimester: no known fetal risks, but use only if clearly needed.
No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled out; use only if clearly needed.
Acarbose is excreted into breast milk in negligible amounts due to low oral bioavailability and high molecular weight. M/P ratio not established. Considered compatible with breastfeeding; monitor infant for gastrointestinal effects (e.g., flatulence, diarrhea).
No data on presence in human milk. M/P ratio unknown. Consider benefit of breastfeeding versus potential risk to infant.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to minimal systemic absorption. Initiate at 25 mg three times daily with meals; titrate based on 1-hour postprandial glucose levels.
No pharmacokinetic studies in pregnancy; dosing adjustments not established. Monitor glycemic control closely and adjust as needed per clinical response.
Acarbose delays carbohydrate absorption by inhibiting alpha-glucosidase in the brush border of the small intestine. It should be taken with the first bite of each main meal. Its efficacy is limited by gastrointestinal side effects (flatulence, diarrhea) due to undigested carbohydrates reaching the colon. Not recommended in patients with inflammatory bowel disease or colonic obstruction. Hypoglycemia from acarbose (rare in monotherapy) must be treated with oral glucose or milk, not sucrose or complex carbohydrates, since their digestion is blocked. Acarbose can cause isolated transaminase elevations; monitor LFTs if symptoms occur.
Miglitol is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is not effective for type 1 diabetes. Monitor liver enzymes; cases of hepatitis have been reported. Do not use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Hypoglycemia must be treated with oral glucose (dextrose), not sucrose because sucrase is inhibited. Take with the first bite of each main meal.
Take acarbose with the first bite of each main meal; do not take it between meals.,Common side effects include gas, bloating, and diarrhea, which may improve over time.,If you experience low blood sugar, treat it with glucose tablets, juice, or regular soda, not candy or fruit juice (acarbose blocks their digestion).,Tell your doctor if you develop jaundice or abdominal pain, as liver problems can occur.,This medication is not for weight loss and does not affect insulin secretion.
Take miglitol three times daily at the start of each main meal (with the first bite).,If you miss a dose, skip it if the meal is already finished; do not double the dose.,Common side effects include flatulence, diarrhea, and abdominal pain; these may decrease over time.,If hypoglycemia occurs, use glucose tablets or gel; table sugar (sucrose) will not work.,Inform your doctor if you have a history of kidney disease, inflammatory bowel disease, or intestinal obstruction.
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the gut, leading to a reduction in postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity in some patients, potentially increasing the risk of hypoglycemia when combined with acarbose. The interaction is primarily due to additive effects on glucose metabolism, and patients should be monitored for signs of hypoglycemia, particularly during initiation or dose adjustments."
"Chlorothiazide, a thiazide diuretic, can decrease the therapeutic efficacy of acarbose, an alpha-glucosidase inhibitor used for postprandial glycemic control in type 2 diabetes. The hypokalemia induced by chlorothiazide may impair insulin secretion and reduce the glucose-lowering effect of acarbose, potentially leading to elevated postprandial glucose levels. This interaction may necessitate dose adjustments or alternative antihyperglycemic therapy to maintain glycemic control."
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, thereby reducing postprandial hyperglycemia. Selegiline, a selective MAO-B inhibitor at therapeutic doses, can potentiate the hypoglycemic effect of acarbose by an unknown pharmacodynamic mechanism, potentially leading to episodes of hypoglycemia. This interaction is of particular concern in patients with diabetes mellitus who are co-prescribed these agents, as the combined effect on glucose homeostasis may require dose adjustments or enhanced monitoring."
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, reducing postprandial hyperglycemia. Stanozolol, an anabolic steroid, can increase insulin sensitivity and enhance glucose utilization, potentially leading to additive hypoglycemic effects. Concurrent use may result in unexpectedly low blood glucose levels, especially in diabetic patients on insulin or sulfonylureas."
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate absorption and reduces postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity or alter glucose metabolism, potentially increasing the hypoglycemic effect when combined with miglitol. This interaction could result in additive blood glucose lowering and an elevated risk of hypoglycemic episodes, particularly in diabetic patients."
"Saquinavir, a protease inhibitor used in HIV therapy, may decrease the therapeutic efficacy of miglitol, an alpha-glucosidase inhibitor for type 2 diabetes, by potentially increasing gastrointestinal motility or altering gut enzyme activity. This interaction can lead to reduced miglitol absorption and diminished postprandial glycemic control, increasing the risk of hyperglycemia in diabetic patients. Clinical outcomes include elevated blood glucose levels and potential loss of diabetes management."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACARBOSE vs MIGLITOL, answered by our medical review team.
ACARBOSE is a Alpha-Glucosidase Inhibitor that works by Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.. MIGLITOL is a Alpha-Glucosidase Inhibitor that works by Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACARBOSE and MIGLITOL depend on the specific clinical indication. These are both Alpha-Glucosidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACARBOSE is: Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.. The standard adult dose of MIGLITOL is: 25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACARBOSE and MIGLITOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACARBOSE is classified as Category C. Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposu. MIGLITOL is classified as Category A/B. No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.